Skip to main content
. 2020 May 29;10(4):673–697. doi: 10.1016/j.jcmgh.2020.05.007

Figure 10.

Figure 10

IL23 induces IL12 and recombinant IL23 selectively activates the IL23-receptor complex. (A and B) MDMs (n = 4; similar results in an additional n = 4) were treated for the indicated times with (A) 10 ng/mL IL23 ± neutralizing anti-IL12p35 antibodies (or isotype control) or (B) 10 ng/mL IL12 ± neutralizing anti-IL23p19 antibodies (or isotype control). Cytokine secretion. (C and D) MDMs were treated with (C) IL23 or (D) IL12 ± neutralizing anti-IL23p19 or neutralizing anti-IL12p35 antibodies (or isotype control). Fold phosphoprotein expression by flow cytometry at 15 minutes (early time point examined so as to assess outcomes before autocrine/paracrine effects of secreted cytokines) (n = 12 from 2 independent experiments for p-PDK1, p-JAK2, and p-TYK2; n = 6 for p-STAT3). Means + SEM. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, †P < 1 × 10-4, and ††P < 1 × 10-5. Tx, treatment.